Tuesday, April 5, 2011
Stealth Peptides Inc., of Boston, reported results of a Phase I study in healthy volunteers of Bendavia, a compound that targets the mitochondrion to treat ischemia reperfusion injury. Volunteers received a single dose of Bendavia administered as an intravenous infusion over an extended period. Bendavia appears to be safe and well tolerated at the dose evaluated, with no serious adverse events reported.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.